Home Biological science Gimv strengthens its position in life sciences venture capital with the creation of a new dedicated platform

Gimv strengthens its position in life sciences venture capital with the creation of a new dedicated platform


Gimv AG

Gimv is getting stronger his position in life sciences capital risk with the creation of a new dedicated platform

  • Trim-out of New Life sciences Platform of Gimv’s Existing health Platform

  • Bbuilt on Gimv’s more … than 40 years of experience of successful investis lying in the area

  • ambition of grow the life sciencess Venture capital portfolio to about twenty companies, from 12 p.m. today

  • In line with Gimv commitment to continue to invest in innovative research and badded value for society, the patients and shareholders

  • Bram Vanparys* appointed Managing Partner, Head of Life Sciences

Antwerp, BelgiumJune 15, 2022: Gimv (Euronext – GIMB), a European investment company, listed on Euronext Brussels, with 40 years of experience in private equity and venture capital, announces the creation of its fifth investment platform focused on venture capital investments in innovative life science ventures.

Following strong growth within Gimv’s existing healthcare platform, a dedicated life sciences platform will strengthen Gimv’s role in the international ecosystem of life science venture capital firms. The main investment objective remains the search for solutions to the many unmet health care needs.

The Life Sciences platform builds on the success and excellent returns generated by portfolio companies over four decades, including companies like Ablynx, where Gimv was a founding investor and Covagen, which was acquired by Johnson & Johnson . Current investments include Precirix, ImCheck and ImmunOs, which recently raised $74m in a Series B funding round led by Gimv.

With this new platform, Gimv can further strengthen its ability to invest larger tickets, with a typical initial investment of EUR 10-15 million per company. With the aim of nearly doubling its current portfolio to around 20 companies, Gimv will maintain its Series A and B investment strategy with a particular focus on drug development. Other areas of investment will include medical technology, digital health, life science tools and agri-biotechnology.

Bram Vanparys*, who was a partner in the Gimv Healthcare platform, has been appointed to lead the new team of seven venture capital professionals dedicated to life sciences, which will be further expanded over the next few years.

Koen Dejonckheere, Cchief Eexecutive Oofficer of Gimv, commented: “In addition to our existing four investment platforms Sustainable Cities, Smart Industries, Consumer Goods and Healthcare, our new Life Sciences platform will allow us to build on Gimv’s strong track record of investments in life sciences. . Furthermore, it will help strengthen our position at the forefront of the European life sciences ecosystem, recognized globally for its innovation and excellence in the development of life-saving therapies.

Bram Vanparys*, Manager Partner and Boss of Life Sscience at Gimv, said: “The launch of the new Life Sciences platform represents an exciting new step for Gimv in the sector. We will be able to focus more of our efforts on providing venture capital to companies with promising new therapies for patients. Together with the rest of the team, I look forward to this new chapter for Gimv.

bart Diels**, Managing Partner and Head of Healthvsare at Gimvadded: “After building a strong portfolio within the Healthcare platform, the time has come to launch a focused Life Sciences platform. Having a VC-centric Life Sciences platform separate from a PE-centric healthcare platform allows for greater focus for both teams while preserving potential synergies. We believe that our specialized approach, supported by an experienced team, is one of the main differentiators of Gimv’s investment strategy. I am proud of what we have accomplished together over the past few years and have great confidence in Bram and his team to further strengthen our Life Sciences franchise.


Bram Vanparys*
Email: Bram.Vanparys@gimv.com
Such. : +32 3 290 21 00

Consilium Strategic Communications
Amber Fennell, Lucy Featherstone
E: Gimv@consilium-comms.com
T: +44 (0)20 3709 5700

Notes to Editors

Afight gimv
Gimv is a European investment company, listed on Euronext Brussels. With 40 years of experience in private equity and venture capital, Gimv currently has €2 billion in assets under management. The portfolio comprises approximately 60 portfolio companies, with a combined turnover of 3.1 billion euros and more than 18,000 employees.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv’s five investment platforms are Consumer, Healthcare, Life Sciences, Smart Industries and Sustainable Cities. Each platform works with a team experienced in Gimv’s home markets of Benelux, France and DACH, supported by an extensive international network of experts.

Further information about Gimv is available at www.gimv.com.

* Acting on behalf of Root bv

** Acting on behalf of Candor Consult bv